The effects of 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) and four novel synthetic analogues (EB1089, KH1060, KH1230 and CB1093) on IGF-I-stimulated growth of MCF-7 human breast cancer cells have been determined. A significant time-and dose-dependent inhibition of IGF-I-stimulated cell growth was seen with EB1089, such that after 7 days of treatment with 10 8 M EB1089, the mitogenic effect of IGF-I (30 ng/ml) was negated.
Introduction
The active hormonal form of vitamin D, 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) has potential as a therapeutic agent in hyperproliferative disorders, but is limited by its strong calcaemic activity, leading to hypercalcaemia (Koeffler et al. 1985) . Therefore, new vitamin D analogues are being developed with increased growthinhibitory effects and reduced calcaemic activity. Most analogues synthesized have modifications in the C-17 side chain of the vitamin D molecule, which seems to be the most effective approach to separate calcaemic from antiproliferative activities. Vitamin D derivatives have been shown both to inhibit the proliferation of cultured human breast cancer cells and to cause regression of experimental mammary tumours in vivo (Colston et al. 1992a ,b, Mathiasen et al. 1993 , Saez et al. 1993 .
Breast cancer is the most frequent malignancy of females in many western countries (van der Burg & de Laat 1991) . Breast cancer cells both secrete and respond to a variety of autocrine/paracrine growth factors, including insulin-like growth factor-I (IGF-I) (Stewart et al. 1992) , and are specifically dependent on the presence of these growth factors for their continual proliferation (Fontana et al. 1991) . IGF-I is a potent stimulator of breast carcinoma proliferation (Cullen et al. 1990 , Adamo et al. 1992 and is more potent than IGF-II (Osborne et al. 1990 ). In the case of oestrogen receptor (ER)-positive MCF-7 cells, IGF-I has been reported to be the most potent mitogen studied (Karey & Sirbasku 1988) . A recent study showed that total plasma IGF-I levels are higher in women with breast cancer (Peyrat et al. 1993) , suggesting that enhanced IGF-I activity may play a significant role in the development of breast cancer (Kazer 1995) . The mitogenic actions of IGF-I are initiated by interaction with its receptor (IGF-IR) located in the plasma membrane of the target cells, which exhibits a high affinity for IGF-I and a low affinity (about 1% of IGF-I) for insulin (Froesch et al. 1985) . Breast cancer cells express higher levels of IGF-IR (Furlanetto & DiCarlo 1984) , when compared with normal breast tissue cells (Papa et al. 1993) .
The growth of many breast cancer cells is regulated by oestradiol. In ER-positive breast cancer cell lines, oestradiol stimulates cell growth by a receptor-mediated pathway. Oestradiol also induces an increase in IGF-IR expression (LeRoith et al. 1995) . Anti-oestrogens are effective in controlling the growth of oestrogen-responsive tumours and cells (Wakeling & Bowler 1992 , Vink-van Wijngaarden et al. 1994 . 1,25(OH) 2 D 3 also inhibits oestrogen-induced growth of the oestrogen-responsive MCF-7 cell line (Demirpence et al. 1994) .
Retinoids are known to inhibit breast cancer cell growth (Moon et al. 1983 , Anzano et al. 1994 , Bentel et al. 1995 . The cellular activity of vitamin D and retinoids is mediated by nuclear receptors which belong to a superfamily that includes steroid and thyroid hormone receptors (Evans 1988) , and molecular interactions between nuclear receptors for vitamin D and retinoic acid at the level of target gene transcription have been reported. It has been proposed that the vitamin D receptor can bind to DNA as a heterodimeric complex with the retinoid X receptor for which 9-cis-retinoic acid (9-cis-RA) is the ligand (Yu et al. 1991 , Levin et al. 1992 , resulting in transcriptional activation or repression of specific responsive genes. Retinoids have been shown to have synergistic effects with 1,25(OH) 2 D 3 in the inhibition of proliferation in the human breast cancer cell line T 47D (Bollag 1994) .
At present, the mechanisms of suppression of tumour growth by 1,25(OH) 2 D 3 and its analogues are not well understood. One possible mechanism is by modulating the action of IGF-I in promoting growth of breast cancer cells. As part of ongoing studies to elucidate the mechanisms underlying the antiproliferative effects of vitamin D, we have determined the effects of 1,25(OH) 2 D 3 and its new synthetic analogues EB1089, KH1060, KH1230 and CB1093 on the IGF-I-stimulated growth of MCF-7 breast cancer cells. In addition, the effects of the vitamin D analogues on IGF-IR have been assessed.
Materials and Methods

Compounds
,10-secopregna-(5Z,7E),10(19)-triene), KH1060, KH1230 and CB1093 were gifts from Dr L Binderup (Leo Pharmaceutical Products, Ballerup, Denmark). All-trans-retinoic acid (ATRA) was purchased from Sigma Chemical Co (Poole, Dorset, UK). 9-cis-RA was a gift from Dr M Uskokovic (Hoffmann-La Roche, Nutley, NJ, USA). ICI 182, 4, 5, 5, nonyl]oestra-1,3,5(10)-triene-3,17 -diol) was kindly provided by Dr A Wakeling (Zeneca Pharmaceuticals, Macclesfield, Cheshire, UK). All the compounds were dissolved in absolute ethanol for in vitro studies. In all experiments the final concentration of ethanol in tissue culture medium did not exceed 0·1%.
Peptides
Human recombinant IGF-I from R&D Systems (Europe Ltd, Abingdon, Oxfordshire, UK) was diluted in 10 m Tissue culture medium and reagents were obtained from Gibco (Paisley, Strathclyde, UK). All other analytical grade reagents were obtained from Sigma.
Cell culture
The MCF-7 human breast cancer cell line was routinely maintained in Dulbecco's modified Eagle's medium, supplemented with 100 U penicillin/ml, 100 µg streptomycin/ml and 5% fetal calf serum at a constant temperature of 37 C with a humidified atmosphere of 5% CO 2 . The cells were passaged once a week. For growth experiments, cells were trypsinized and 1 10 4 cells were plated in 12 mm diameter wells (48-well plate) in 0·5 ml of the growth medium (RPMI 1640 medium containing 2·5% charcoal-stripped fetal calf serum with the above mentioned supplements) or 2 10 4 cells were plated in 16 mm diameter wells (24-well plate) in 1 ml of the growth medium. The cells were cultured for 65-68 h before treatment. Cells were treated with IGF-I, the vitamin D derivatives or other test compounds in RPMI 1640 medium containing 1% charcoal-stripped fetal calf serum with the above mentioned supplements for 3-10 days with a medium change every 2-3 days. Control cultures were incubated in medium containing vehicle alone. Vehicle for IGF-I was 10 m HCl (final concentrationc30 µ), and for vitamin D derivatives it was ethanol.
Proliferation assay
A modification of the crystal violet assay was used to determine MCF-7 cell proliferation (Wosikowski et al. 1993) . On selected days after removal of the incubation medium, the cell monolayer was washed twice with PBS. Cells were fixed and stained by adding 0·5 ml 0·5% crystal violet solution in 25% methanol. After 10 min, the excess dye was removed by washing three times with distilled water and the cells were then air-dried for at least 20 h. The incorporated dye was solubilized in 2 ml (16 mm well) or 1 ml (12 mm well) 0·1  sodium citrate solution in 50% ethanol and 100 µl was transferred to a 96-well plate. In order to determine cell number in each sample, the optical density (OD) was measured directly at a wavelength of 550 nm in a microplate reader (Titertek Multiskan). The OD of each sample was then compared with a standard curve, in which the OD was directly proportional to known cell numbers.
IGF-I-binding assays were performed essentially as described by Stewart et al. (1990) . IGF-I binding was measured with MCF-7 cell monolayers in 24-well plates. Cells were washed with PBS and incubated for 2·5 h at 4 C with 50 000-80 000 c.p.m. of 125 I-IGF-I (specific activity 2000 Ci/mmol) in 0·2 ml PBS containing 1 mg/ ml BSA. Non-specific binding was assessed by incubating cell cultures with 125 I-IGF-I in the presence of 100 n unlabelled IGF-I. After the incubation, the cell layer was washed three times with cold PBS and dissolved in 0·5  NaOH. Radioactivity (c.p.m.) was measured in a gammacounter (Packard, Cobra Auto-gamma). Results are expressed as c.p.m./5 10 5 cells. Cell numbers were assessed by crystal violet assay using replicate cell samples treated in the same way and cultured in the same microwell plates as those for the IGF-I-binding assay.
To determine 
Western analysis
The expression of IGF-IR in MCF-7 cells was determined by Western analysis with a polyclonal antibody recognizing the -subunit of IGF-IR. For the IGF-IR immunoblots, total protein was fractionated by SDS-PAGE on 7·5% gels, followed by electroblotting of the protein on to Hybond C-super nitrocellulose membrane (Amersham). The membrane was incubated (1 h) with 0·5 µg/ml of a rabbit polyclonal antibody (N-20). All subsequent steps were performed according to the protocol provided by Santa Cruz Biotechnology, Inc. Densitometry was performed on a MicroTek Scanmaker flat bed scanner (Redondo Beach, CA, USA) and quantified with NIH Image 1·52 software.
Statistical methods
Data were analysed by ANOVA using the software program, Statview (Abacus Concept, Inc., Berkeley, CA, USA).
Results
Effects of vitamin D derivatives on IGF-I-stimulated growth of MCF-7 cells
To investigate effects of vitamin D derivatives on IGF-Istimulated growth of MCF-7 cells, cultures were incubated for 3, 7 and 10 days in the presence or absence of the vitamin D analogue EB1089 (10 8 M) alone or in combination with IGF-I (30 ng/ml). A significant timedependent inhibition of IGF-I-stimulated cell growth was seen, which was evident after 3 days of treatment with EB1089 and was maintained until the end of the study at day 10. After 7 days of treatment, the combination of IGF-I and EB1089 inhibited MCF-7 cell growth to such an extent that the mitogenic effect of IGF-I was negated (Fig. 1a) . EB1089 (10 8 M) alone produced a significant inhibition of cell growth compared with control cultures (7 and 10 days treatment). The effects of EB1089 on IGF-I-stimulated growth were dose-dependent over the range 10 10 10 8 M at 7 days of treatment (Fig. 1b) . 10 9 M and 10 8 M EB1089 completely abrogated the mitogenic effect of IGF-I (1, 10 and 30 ng/ml).
The anti-IGF-I effects of EB1089 were further compared with those of the native hormone 1,25(OH) 2 D 3 and other analogues (KH1060, KH1230 and CB1093) by treating MCF-7 cells with IGF-I (30 ng/ml) in the presence or absence of between 10 10 and 10 7 M vitamin D compounds for 7 days (Fig. 2) . Over the dose range 10 9 -10 8 M, 1,25(OH) 2 D 3 was ineffective in inhibiting IGF-I-stimulated cell growth, while the analogues EB1089, KH1060, KH1230 and CB1093 each displayed significant antiproliferative actions. To identify whether 1,25(OH) 2 D 3 was also effective in inhibiting IGF-I-stimulated MCF-7 cell proliferation, the maximal dose for this compound was increased to 5 10 8 M, and at this concentration 1,25(OH) 2 D 3 was capable of decreasing the mitogenic effect of IGF-I. The maximal growthinhibitory effect was similar (85%) for 1,25(OH) 2 D 3, KH1060 and EB1089 and was reached at approximately 10 9 M KH1060, 10 8 M EB1089 and 5 10 8 M 1,25(OH) 2 D 3 . The concentrations of the analogues needed to achieve 50% inhibition of cell growth (IC 50 ) were assessed, and on the basis of these concentrations, the relative potencies with respect to 1,25(OH) 2 D 3 were calculated. KH1230 displayed a small increased potency, whereas CB1093, EB1089 and KH1060 were clearly more potent than 1,25(OH) 2 D 3 : 18, 98 and 1000 times respectively (Table 1) .
Comparison of the effects of vitamin D derivatives, retinoids and anti-oestrogen on MCF-7 cell growth in the presence or absence of IGF-I
Retinoids and anti-oestrogens are also known to inhibit MCF-7 breast cancer cell growth. In order to compare the efficacy of the vitamin D derivatives, retinoids and ICI 182,780 on IGF-I-stimulated and unstimulated growth, MCF-7 cells were incubated for 7 days with or without IGF-I (30 ng/ml) in the presence or absence of between 10 10 and 10 7 M concentrations of these compounds. The concentrations needed to achieve 50% inhibition of MCF-7 cell cultures relative to control (vehicle alone for
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unstimulated growth and IGF-I alone for IGF-Istimulated growth) were determined and are shown in Table 1 . Results showed that EB1089 and ICI 182,780 inhibited IGF-I-stimulated growth of these cells similarly. In contrast, neither ATRA nor 9-cis-RA were effective in limiting the cellular responsiveness to IGF-I. The proliferation of cultures incubated with IGF-I (30 ng/ml) together with ATRA or 9-cis-RA (10 10 -10 7 M) for 7 days was not significantly reduced compared with IGF-I alone; on the contrary, ATRA weakly increased the stimulatory effects of the growth factor (P<0·05). A similar trend was also seen with 9-cis-RA but the difference from control did not reach significance. The ratio of IC 50 with and without IGF-I indicates the different effects of these compounds on the IGF-I-stimulated and unstimulated growth. The concentrations of the retinoids producing 50% inhibition for IGF-I-stimulated growth are much higher (about 30-and 60-fold for ATRA and 9-cis-RA respectively) than those for unstimulated growth (Table 1) .
Interaction of vitamin D analogue with anti-oestrogen or retinoids on IGF-I-stimulated growth of MCF-7 cells
The interaction of vitamin D analogue EB1089 and the pure anti-oestrogen ICI 182,780 or retinoids in MCF-7 cell growth was studied in the presence of IGF-I (30 ng/ ml) for 7 days. As shown in Fig. 3a , combination of 10 9 M EB1089 and ICI 182,780 exerted a distinct co-operative effect on inhibition of IGF-I-stimulated cell growth compared with the actions of either compound alone. Regarding treatment of cells with 10 9 M EB1089 and 10 8 M ATRA or 9-cis-RA alone or in combination in the presence of IGF-I (Fig. 3b) , results showed that neither retinoid alone was effective in inhibiting IGF-Istimulated cell growth. However, the combination of EB1089 with ATRA as well as the combination of EB1089 with 9-cis-RA produced additional inhibitory effects on IGF-I-stimulated cell growth in comparison with that seen with EB1089 alone.
Effects of vitamin D derivatives on IGF-I binding to MCF-7 cell membranes
Experiments were undertaken to assess whether pretreatment of cells with vitamin D derivatives could diminish responsiveness to IGF-I via changes in IGF-I binding. Initial studies examined the specificity of 125 I-IGF-I binding. Monolayers of MCF-7 cells were incubated with 125 I-IGF-I in the presence and absence of various concentrations of competing unlabelled IGF-I and insulin. The non-specific binding was approximately 10% of the total binding and was subtracted from total binding values. Figure 4 shows the ability of radioinert IGF-I and insulin to displace 125 I-IGF-I binding to MCF-7 cell membranes. 125 I-IGF-I binding was completely abolished by incubation with unlabelled IGF-I (10 7 M). A 50% displacement was obtained with IGF-I at 2 10 9 M and with insulin at 5 10 7 M.
MCF-7 cells were pretreated with EB1089 (10 9 or 5 10 9 M) for 6 days and then incubated with 125 I-IGF-I alone or in the presence of excess IGF-I (10 7 M). Figure 5a shows that EB1089 down-regulated the level of 125 I-IGF-I binding to MCF-7 cell membranes in a dosedependent manner. In cells cultured with 10 9 M and 5 10 9 M of EB1089, binding of 125 I-IGF-I was reduced to 74 and 50% of control levels respectively. 1,25(OH) 2 D 3 (5 10 8 M) and the pure anti-oestrogen, ICI 182,780 (5 10 9 M), also decreased the IGF-I binding to MCF-7 cell membranes (Fig. 5b) .
The number and affinity of 125 I-IGF-I-binding sites on MCF-7 cell membranes were determined by Scatchard analysis (Fig. 6) , which revealed that pretreatment of cells with EB1089 (5 10 9 M) for 6 days reduced maximal binding from 10·7 fmol/5 10 5 cells in control cultures to 5·0 fmol/5 10 5 cells in EB1089-treated cells with no marked change in affinity (K d =0·38 and 0·26 n for control and EB1089-treated cultures respectively). (Fig. 7) .
Effects of vitamin D derivatives on IGF-IR expression
Discussion
In this report we demonstrate that vitamin D derivatives limit the responsiveness of MCF-7 cells to the mitogenic actions of IGF-I. Treatment of cells with combinations of IGF-I and the synthetic vitamin D analogues resulted in a striking decrease in IGF-I-induced stimulation of cell proliferation.
A number of previous studies have demonstrated that 1,25(OH) 2 D 3 and certain of its synthetic analogues inhibit the autonomous growth of cultured MCF-7 breast cancer 
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Journal of Endocrinology (1997) 154, 495-504 cells (Saez et al. 1993 , Demirpence et al. 1994 , Colston et al. 1995 (Bikle 1992) , which may increase the free fraction of these analogues in culture medium containing serum and may be associated with their increased potency. A previous report showed that 1,25(OH) 2 D 3 at 10 7 M inhibited IGF-I-stimulated growth in human osteosarcoma cells (Pirskanen et al. 1993) . However, the mechanism has not been elucidated. Our results agree with those obtained by Vink-van Wijngaarden et al. (1996) , who demonstrated that 1,25(OH) 2 D 3 and EB1089 at 10 9 and 10 7 M blocked the mitogenic activity of an IGF-I analogue and insulin in MCF-7 cells and this was associated with inhibition of insulin-induced c-fos mRNA expression, a possible intracellular mediator of the insulin-IGF mitogenic signal.
9-cis-RA and ATRA have both been shown to inhibit the in vitro growth of ER-positive human breast cancer cells. The ability of the retinoids and vitamin D derivatives to limit the mitogenic effects of IGF-I was compared. Both 9-cis-RA and ATRA over the concentration range 7 M produced a significant and dosedependent inhibition of MCF-7 cell growth in the absence of IGF-I but were not effective in limiting responsiveness to this growth factor; indeed 10 10 =10 7 M ATRA weakly increased responsiveness to IGF-I, which is in agreement with results described previously (Bentel et al. 1995) . Only at retinoid levels higher than 10 6 M was significant inhibition of IGF-I-stimulated growth achieved. Thus the concentration of both 9-cis-RA and ATRA producing 50% inhibition of growth in the absence of added IGF-I was insufficient to produce 50% inhibition of growth in the presence of the growth factor, whereas the concentrations of vitamin D derivatives required to achieve this degree of growth inhibition were similar for both experimental conditions. These data indicate that vitamin D derivatives are more effective than retinoids in inhibition of IGF-I mitogenic activity.
The present study shows that the anti-IGF-I activity of the vitamin D analogue EB1089 was strikingly increased by interaction with the pure anti-oestrogen, ICI 182,780. Combinations of 10 9 M EB1089 and ICI 182,780 in the presence of IGF-I for 7 days exerted an additional effect on inhibition of IGF-I-stimulated cell growth compared with the actions of either compound alone. Similar co-operative effects were also achieved by combination of EB1089 and the retinoids, ATRA and 9-cis-RA. The action of retinoids (10 8 M) in increasing IGF-I-stimulated growth was reversed by combination with EB1089 (10 9 M), and furthermore the inhibition of IGF-I-stimulated cell growth was augmented from 31% (EB1089 alone) to 59% by combined treatment with either retinoid.
The underlying mechanisms by which vitamin D derivatives are able to limit responsiveness to IGF-I were investigated by determining whether these compounds are capable of altering IGF-I receptor expression. Using ligand-binding techniques, effects of vitamin D derivatives on 125 I-IGF-I binding to MCF-7 cell membranes have In contrast, 50% displacement was achieved with insulin at 5 10 7 M. This pattern of potency indicates that binding was mainly to the IGF-IR, as previously reported for MCF-7 cells (Stewart et al. 1990 ) and not to the insulin receptor. IGF-I may also bind to IGF-IIR and a number of IGF-binding proteins (IGFBPs), but since insulin does not bind to these two classes of sites it will not compete with radiolabelled IGF-I for binding (Heath et al. 1993) . The difference (18%) in maximal displacement of 125 I-IGF-I between radioinert IGF-I and insulin may indicate the amount of binding to IGFBPs and/or IGF-IIR.
Treatment of MCF-7 cells with increasing doses of EB1089 for 6 days led to a decrease in specific binding of 125 I-IGF-I to cell membranes. Similar effects were seen with 1,25(OH) 2 D 3 and the anti-oestrogen ICI 182,780. Scatchard analysis showed that treatment of cells with EB1089 reduced maximal binding to approximately 50% of control value. Vink-van Wijngaarden et al. (1996) showed that 125 I-IGF-I binding to cell membranes was increased about 1·5-to 3-fold by vitamin D compounds. These divergent results may be attributable to different MCF-7 sublines and/or different experimental conditions, such as serum-free vs serum-containing medium or time and frequency of treatment with vitamin D compounds. Differences in cell density between treated and control cultures may also be a confounding factor (Larsen & Darbre 1996) . However, our results obtained by Western analysis also demonstrated that the expression of IGF-IR was down-regulated by vitamin D derivatives, suggesting that effects of vitamin D derivatives in limiting responsiveness of breast cancer cells to the mitogenic IGF-I may be via reduction of IGF-IR. However, effects on expression and regulation of IGFBPs cannot be excluded.
Oestradiol sensitizes the MCF-7 cell line to the mitogenic effects of insulin and IGF-I, which is mediated through the IGF-IR. A previous report has demonstrated that the levels of IGF-IR protein expression and its mRNA transcription are increased 7-and 6·5-fold respectively by oestradiol in the MCF-7 cell line (Stewart et al. 1990) . A positive correlation between ER levels and IGF-IR levels in breast tumour tissue (Peyrat et al. 1988) and breast cancer cells (Pollak et al. 1992) has been shown. Anti-oestrogen-induced down-regulation of IGF-IR has been reported in ER-positive breast cancer cells (Winston et al. 1994 ) and our results also show that the pure anti-oestrogen ICI 182,780 inhibits IGF-I-stimulated growth of these cells. The vitamin D analogue EB1089 down-regulates the expression of ER protein in MCF-7 cells and limits cellular responsiveness to 17 -oestradiol ( James et al. 1994) , both in terms of cell growth and expression of oestrogen-regulated genes. Vitamin D compounds may also modulate sensitivity of cells to IGF-I by directly modulating IGF-IR expression or indirectly via oestrogen-response pathways.
In summary, our findings demonstrate that vitamin D derivatives limit responsiveness of MCF-7 cells to the mitogenic effects of IGF-I. In addition we have demonstrated marked co-operative effects between the vitamin D analogue EB1089 and the anti-oestrogen ICI 182,780, indicating that combined treatment with vitamin D and anti-oestrogen may be an effective therapeutic regimen. Effects on IGF-I responsiveness may be mediated via decreased receptor expression.
